While the maintenance of a Buy rating suggests continued confidence in Ocular Therapeutix's fundamentals and potential growth, the reduction in the price target could reflect adjustments in valuation metrics, market conditions, or company-specific factors. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the implications.